Cosmos Holdings, Inc. COSM 深 滬
等待開盤 09-30 09:30:00 美东时间
1.0636
-0.016
-1.52%
華盛通- 最 高1.10
- 今 開1.10
- 成交量 54.30万股
- 最 低 1.02
- 昨 收 1.08
- 總市值 3213.55万
- 52周最高 1.28
- 市盈率 靜 --
- 換手率 1.80%
- 52周最低 0.2801
- 委 比 -94.52%
- 總股本 3021.39万
- 歷史最高 23.84
- 量 比 0.66
- 振 幅 7.41%
- 歷史最低 0.2801
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cosmos Health CEO Issues Letter To Shareholders
Dear Fellow Shareholders,Cosmos Health stands at a defining moment in its journey. Over the past year, we have made decisive progress - refining our strategy, reinforcing our operations, and positioning every business
09-29 20:17
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
Cosmos Health Inc. reported significant progress in its strategic pillars, including expanding manufacturing capabilities, global brand growth, R&D advancements, and financial restructuring. CEO Greg Siokas highlighted key achievements such as securing a $300 million digital asset facility, Cana Laboratories' expansion and contract wins, and Sky Premium Life's rapid international expansion. Financial performance showed revenue growth and margin i...
09-29 12:00
Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually
Cosmos Health Inc. subsidiary, Cana Laboratories, has signed a contract manufacturing agreement with Medical Pharmaquality S.A. to produce MYCOFAGYL® pessaries, a dual-action treatment for vaginal infections. The product combines Metronidazole and Nystatin to address bacterial vaginosis and yeast infections. With an annual production capacity of 3 million pessaries, this agreement underscores Cana's expertise in high-quality pharmaceutical manufa...
09-25 12:00
Cosmos Health Expects Gross Margins Of ~75% And Strong Cash Flow From Sky Premium Life U.S. Operations; NOOR Collagen Alone Projected To Generate Over $12M In Annualized Revenue
The Company anticipates strong gross margins of approximately 75% and significant cash flow generation from its Sky Premium Life U.S. operations. NOOR Collagen alone is projected to generate more than $12 million in
09-22 20:18
Cosmos Health Commences U.S. Operations Launching Proprietary Sky Premium Life Food Supplements Brand
Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its
09-22 20:17
Cosmos Health shares are trading higher after signing a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman.
Cosmos Health shares are trading higher after signing a distribution agreement ...
09-11 20:03
Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
Cosmos Health Inc. announced that its subsidiary, Sky Pharm SA, has signed a distribution agreement with Scientific Pharmacy LLC in Oman for its Sky Premium Life food supplement products. Scientific Pharmacy, part of Planet Pharmacies and owned by Gulf Pharmaceutical Industries (Julphar), is a leading healthcare company in Oman and the GCC region. The agreement covers regulatory compliance, product registration, distribution, marketing, logistics...
09-11 12:00
三大重磅眼药临近上市，兆科眼科-B（6622.HK）的价值重估开始了
今年，港股创新药势不可挡，成为资本市场的重磅热点。 数据最具说服力，港股创新药概念指数从年初至今涨幅已超100%，不仅大幅跑赢恒生指数，更以扎实的上涨态势重塑了...
09-01 08:44
Cosmo Pharmaceuticals Gains CHMP Approval for Winlevi® in Europe
COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has provided an announcement. Cosmo P...
08-27 13:35
质押、ETF、储备：以太坊的估值是否正在被重新定义？
以太坊近期呈现三大关键趋势：质押持续增长，形成了链上“无风险利率”；现货ETF获批并吸引大量资金流入；多家美国上市公司将其纳入储备资产。这些因素相互促进，使ETH从代币转变为金融基础设施核心资产。2025年，随着质押收益率提升、ETF渠道拓宽及企业储备增加，以太坊将成为全球账本的流动性核心，数字资产的金融属性进一步强化。
08-26 02:33
